49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-022101-18-HR (EUCTR) | 31/03/2014 | 17/10/2014 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 17.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: Not available Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3 | Serbia;United States;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Russian Federation;Israel;Chile;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan | ||
| 2 | EUCTR2010-022101-18-DE (EUCTR) | 20/03/2013 | 10/12/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3 | United States;Belarus;Serbia;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Australia;Peru;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Singapore;Romania;Croatia;Bulgaria;Germany;Japan;New Zealand | ||
| 3 | EUCTR2010-022101-18-GB (EUCTR) | 21/12/2012 | 28/11/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: Not available Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3 | United States;Belarus;Serbia;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Australia;Peru;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Singapore;Romania;Croatia;Bulgaria;Germany;Japan;New Zealand | ||
| 4 | EUCTR2010-022101-18-BG (EUCTR) | 28/08/2012 | 29/08/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 17.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3 | Serbia;United States;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Russian Federation;Israel;Chile;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan | ||
| 5 | EUCTR2010-022101-18-HU (EUCTR) | 17/08/2012 | 17/05/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE) | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3 | South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Croatia;Romania;Bulgaria;Germany;Japan;New Zealand;Serbia;United States;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia | ||
| 6 | EUCTR2010-022101-18-LV (EUCTR) | 10/08/2012 | 28/05/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3 | Serbia;United States;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Croatia;Romania;Bulgaria;Germany;Japan;New Zealand | ||
| 7 | EUCTR2010-022101-18-ES (EUCTR) | 25/05/2012 | 21/05/2012 | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 14.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3 | Serbia;United States;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Croatia;Romania;Bulgaria;Germany;Japan;New Zealand | ||
| 8 | EUCTR2010-022101-18-AT (EUCTR) | 14/05/2012 | 11/04/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 14.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3 | United States;Serbia;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Russian Federation;Chile;Israel;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Tunisia;Latvia;Guatemala;Korea, Democratic People's Republic of;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan |